157 related articles for article (PubMed ID: 23704086)
1. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Kim N; Kang JH; Lee WK; Kim SG; Lee JS; Lee SH; Park JB; Kim KH; Gong YD; Hwang KY; Kim SY
Amino Acids; 2018 Nov; 50(11):1583-1594. PubMed ID: 30105541
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.
Lee SH; Kang JH; Ha JS; Lee JS; Oh SJ; Choi HJ; Song J; Kim SY
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708896
[TBL] [Abstract][Full Text] [Related]
5. A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2.
Kim SY; Keillor JW
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260198
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
Kang JH; Lee SH; Lee JS; Oh SJ; Ha JS; Choi HJ; Kim SY
Cells; 2020 Jun; 9(6):. PubMed ID: 32560270
[TBL] [Abstract][Full Text] [Related]
7. Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival.
Kim SJ; Kim KH; Ahn ER; Yoo BC; Kim SY
Amino Acids; 2013 Jan; 44(1):73-80. PubMed ID: 21960143
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53 in renal carcinoma cells is independent of pVHL.
Stickle NH; Cheng LS; Watson IR; Alon N; Malkin D; Irwin MS; Ohh M
Mutat Res; 2005 Oct; 578(1-2):23-32. PubMed ID: 15998523
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of transglutaminase 2 drives glycolytic metabolism in renal carcinoma cells.
Ku BM; Lee CH; Lee SH; Kim SY
Amino Acids; 2014 Jun; 46(6):1527-36. PubMed ID: 24643363
[TBL] [Abstract][Full Text] [Related]
10. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
Shang D; Ito N; Watanabe J; Awakura Y; Nishiyama H; Kamoto T; Ogawa O
Eur Urol; 2007 Oct; 52(4):1131-9. PubMed ID: 17275163
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
Kim GR; Kang JH; Kim HJ; Im E; Bae J; Kwon WS; Rha SY; Chung HC; Cho EY; Kim SY; Kim YC
Bioorg Chem; 2024 Feb; 143():107061. PubMed ID: 38154386
[TBL] [Abstract][Full Text] [Related]
12. Expression and activity of transglutaminase II in spontaneous tumours of dogs and cats.
Wakshlag JJ; McNeill CJ; Antonyak MA; Boehm JE; Fuji R; Balkman CE; Zgola M; Cerione RA; Page RL
J Comp Pathol; 2006; 134(2-3):202-10. PubMed ID: 16615935
[TBL] [Abstract][Full Text] [Related]
13. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.
Angelo LS; Talpaz M; Kurzrock R
Cancer Res; 2002 Feb; 62(3):932-40. PubMed ID: 11830554
[TBL] [Abstract][Full Text] [Related]
14. Antisense inhibition of transglutaminase 2 affects development of mouse embryo submandibular gland in organ culture.
Lee SK; Kim YS; Lee SS; Lee YJ; Song IS; Park SC; Chi JG; Chung SI
Arch Oral Biol; 2005 Sep; 50(9):789-98. PubMed ID: 15970210
[TBL] [Abstract][Full Text] [Related]
15. IgE production in CD40/CD40L cross-talk of B and mast cells and mediator release via TGase 2 in mouse allergic asthma.
Hong GU; Park BS; Park JW; Kim SY; Ro JY
Cell Signal; 2013 Jun; 25(6):1514-25. PubMed ID: 23524335
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Déjosez M; Ramp U; Mahotka C; Krieg A; Walczak H; Gabbert HE; Gerharz CD
Cell Death Differ; 2000 Nov; 7(11):1127-36. PubMed ID: 11139287
[TBL] [Abstract][Full Text] [Related]
17. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445
[TBL] [Abstract][Full Text] [Related]
18. Tissue transglutaminase-induced down-regulation of matrix metalloproteinase-9.
Ahn JS; Kim MK; Hahn JH; Park JH; Park KH; Cho BR; Park SB; Kim DJ
Biochem Biophys Res Commun; 2008 Nov; 376(4):743-7. PubMed ID: 18809380
[TBL] [Abstract][Full Text] [Related]
19. Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells.
Park KS; Han BG; Lee KH; Kim DS; Kim JM; Jeon H; Kim HS; Suh SW; Lee EH; Kim SY; Lee BI
Cancer Lett; 2009 Feb; 274(2):201-7. PubMed ID: 18851895
[TBL] [Abstract][Full Text] [Related]
20. Role of secreted frizzled-related protein 3 in human renal cell carcinoma.
Hirata H; Hinoda Y; Ueno K; Majid S; Saini S; Dahiya R
Cancer Res; 2010 Mar; 70(5):1896-905. PubMed ID: 20160027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]